To figure out the expression pattern of ZG16B in breast cancer, Ualcan database analysis confirms that ZG16B upregulates in different clinical classifications, including gender, age, and nodal metastasis status; it also demonstrates that ZG16B has significantly high expression in luminal and triple-negative molecular subtypes of breast cancer, while this high expression is not found in HER2-positive subtype (Figure 4). Here, ERBB2 is linked to breast carcinoma.